Theravance Biopharma reports CYPRESS Phase 3 miss but FDA grants Type C meeting to discuss future trialTradingView·12 hours agoTBPH+0.12%
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its ShareholdersMorningStar·Aug 15 at 06:24 AMTBPH+0.12%ZYME-4.52%
Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPHMarket Beat·Aug 15 at 04:20 AMTBPH+0.12%
TBPH: Definitive acquisition agreement, strong YUPELRI® growth, and major cost reductions in Q2 2026Quartr·Aug 10 at 07:49 AMTBPH+0.12%ZYME-4.52%
Theravance BioPharma | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 20.73 MEarnings Watch·Aug 10 at 07:37 AMTBPH+0.12%
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | TBPH Stock NewsStockTitan·Aug 9 at 11:30 PMTBPH+0.12%ZYME-4.52%
Zymeworks revenue drops 90.57% to $4.6 million in FY26 Q2; net loss widens to $45 millionPUBT·Aug 6 at 03:22 PMTBPH+0.12%ZYME-4.52%
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of "Hold" from AnalystsMarket Beat·Aug 3 at 05:29 AMTBPH+0.12%
Swiss National Bank Invests $1.22 Million in Theravance Biopharma, Inc. $TBPHMarket Beat·Aug 1 at 04:12 AMTBPH+0.12%UBS+0.97%
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 | ZYME Stock NewsStockTitan·Jul 15 at 09:00 PMTBPH+0.12%ZYME-4.52%
14:43 ET$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATKprnewswire·Jul 9 at 01:45 PMIRDM-0.42%LCII+0.26%
